Kintara Seeking $15.0M In PIPE
San Diego-based biotech Kintara says it is raising $15.0M in a common stock and warrant offering from unmaned “healthcare-focused institutional investors”. The company–which is novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens–currently trades on the Nasdaq as KTRA. The company said the exclusive placement agent on the offering is H.C. Wainwright & Co. According to Kintara, it intends to use the net proceeds from the offering for funding its clinical studies, working capital and other general corporate purposes, including, but not limited to, funding acquisitions or investments in businesses, products or technologies that are complementary to the Company’s businesses, products and technologies.